Mealey's (May 7, 2019, 11:00 AM EDT) -- WASHINGTON, D.C. — In a May 3 divided ruling, the Federal Circuit U.S. Court of Appeals affirmed a Delaware federal judge’s findings that assertions of patent invalidity raised by two generic drug makers in connection with the painkiller Opana fail (Endo Pharmaceuticals Inc., et al. v. Actavis LLC, et al., No. 18-1054, Fed. Cir., 2019 U.S. App. LEXIS 13348)....